Pelthos Therapeutics (NYSEAMERICAN:PTHS) Director Sells $11,561.76 in Stock

Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) Director Ezra Friedberg sold 558 shares of the company’s stock in a transaction that occurred on Friday, October 2nd. The shares were sold at an average price of $20.72, for a total value of $11,561.76. Following the completion of the transaction, the director directly owned 80,484 shares in the company, valued at $1,667,628.48. The trade was a 0.69% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Pelthos Therapeutics Price Performance

Shares of NYSEAMERICAN PTHS opened at $20.50 on Friday. The firm has a market cap of $78.52 million, a P/E ratio of -0.94 and a beta of 3.07. The business’s 50 day moving average is $24.40 and its 200-day moving average is $25.18. The company has a current ratio of 1.98, a quick ratio of 1.31 and a debt-to-equity ratio of 3.40. Pelthos Therapeutics Inc. has a 1-year low of $18.19 and a 1-year high of $37.50.

Pelthos Therapeutics (NYSEAMERICAN:PTHS) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($6.62) EPS for the quarter. The firm had revenue of $15.60 million during the quarter. Pelthos Therapeutics had a negative net margin of 165.24% and a negative return on equity of 204.71%. Equities research analysts predict that Pelthos Therapeutics Inc. will post -15.22 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its position in Pelthos Therapeutics stock. Pale Fire Capital SE raised its stake in Pelthos Therapeutics Inc. (NYSEAMERICAN:PTHS) by 59.5% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,919 shares of the company’s stock after acquiring an additional 4,819 shares during the quarter. Pale Fire Capital SE owned approximately 0.38% of Pelthos Therapeutics worth $271,000 as of its most recent SEC filing. Institutional investors own 77.96% of the company’s stock.

Wall Street Analyst Weigh In

Separately, Oppenheimer cut their price target on Pelthos Therapeutics from $66.00 to $64.00 and set an “outperform” rating for the company in a research note on Friday, August 14th. Five analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to MarketBeat.com, Pelthos Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $55.40.

About Pelthos Therapeutics

Pelthos Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for pain management. The company’s work is centered on addressing unmet needs in the treatment of acute and chronic pain, including the development of potential alternatives to traditional opioid-based medicines.

Pelthos Therapeutics is advancing investigational drug candidates through preclinical and clinical development. As with other clinical-stage biotechnology companies, its products remain subject to testing and regulatory review, and there is no assurance that any candidate will receive approval or become commercially available.

Publicly available information about the company’s specific product pipeline, operating history, geographic reach and leadership is limited.